Seminars in Oncology
Volume 34 , Pages S25-S30 , April 2007

Treatment of Advanced Pancreatic Cancer

  • Michel Ducreux

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Michel Ducreux, MD, PhD, Institut Gustave Roussy, 39 rue Camille Desmoulins, Villejuif 94805, France.
    • Dr Ducreux has received research grant support from Pfizer, Roche, and Sanofi-Aventis, and has received honoraria or consulting fees from Amgen, Merck Lipha Santé, Pfizer, Roche, and Sanofi-Aventis.
    • ,
  • Valérie Boige

      Affiliations

    • Dr Boige has received research grant support and honoraria or consulting fees from Roche and Sanofi-Aventis.
    • ,
  • David Malka

      Affiliations

    • Dr Malka has received research grant support from Merck Lipha Santé, Pfizer, Roche, and Sanofi-Aventis and has received consulting fees or honoraria from Merck Lipha Santé, Pfizer, Roche, and Sanofi-Aventis.

References 

  1. Glimelius B, Hoffman K, Sjödén PO, et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol. 1996;7:593–600
  2. Palmer KR, Kerr M, Knowles G, et al. Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br J Surg. 1994;81:882–885
  3. Fung MC, Takayama S, Ishiguro H, et al. Chemotherapy for advanced or metastatic pancreatic cancer: Analysis of 4” randomized trials in 3 decades (1974–2002). Gan To Kagaku Ryoho. 2003;30:CVX1101–CVX1111
  4. Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreatic cancer: A randomized trial. J Clin Oncol. 1997;15:2403–2413
  5. Hochster HS, Haller DG, de Gramont A, et al. Consensus report of the International Society of Gastrointestinal Oncology on therapeutic progress in advanced pancreatic cancer. Cancer. 2006;107:676–685
  6. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). [abstr] J Clin Oncol. 2005;23(suppl 1):1
  7. Reni M, Cordio S, Milandri C, et al. Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: A randomised controlled multicentre phase III trial. Lancet Oncol. 2005;6:369–376
  8. Berlin JD, Catalano P, Thomas JP, et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol. 2002;20:3270–3275
  9. Riess H, Helm A, Niedergethmann M, et al. A randomised, prospective, multicenter, phase III trial of gemcitabine, 5-fluorouracil (5-FU), folinic acid vs. gemcitabine alone in patients with advanced pancreatic cancer. [abstr] J Clin Oncol. 2005;23(suppl 1):4009A
  10. Colucci G, Giuliani F, Bebbia V, et al. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma (A prospective, randomized phase III study of the Gruppo Oncologico dell’italia Meridionale). Cancer. 2002;94:902–910
  11. Heinemann V, Quietzsch D, Gieseler F, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol. 2006;24:3946–3952
  12. Lutz MP, Van Cutsem E, Wagener T, et al. Docetaxel plus gemcitabine or docetaxel plus cisplatin in advanced pancreatic carcinoma: Randomized phase II study 40984 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group. J Clin Oncol. 2005;23:9250–9256
  13. Rocha Lima CM, Green MR, Rotche R, et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol. 2004;22:3776–3783
  14. Abou-Alfa GK, Letourneau R, Harker G, et al. Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J Clin Oncol. 2006;24:4441–4447
  15. Bramhall SR, Schulz J, Nemunaitis J, et al. A double-blind placebo-controlled, randomized study comparing gemcitabine and marimastat with gemcitabine and placebo as first-line therapy in patients with advanced pancreatic cancer. Br J Cancer. 2002;87:161–167
  16. Van Cutsem E, van de Velde H, Oettle H, et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol. 2004;22:1430–1438
  17. Plunkett W, Huang P, Searcy CE, et al. Gemcitabine: Preclinical pharmacology and mechanisms of action. Semin Oncol. 1996;23(suppl 10):3–15
  18. Grunewald R, Kantarjian H, Keating MJ, et al. Pharmacologically directed design of the dose rate and schedule of 2′,2′-difluorodeoxycytidine (gemcitabine) administration in leukemia. Cancer Res. 1990;50:6823–6826
  19. Tempero M, Plunkett W, Ruiz V, et al. Randomized phase II comparison of dose-intense gemcitabine: Thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol. 2003;21:3402–3408
  20. Poplin E, Levy DE, Berlin J, et al. Phase III trial of gemcitabine (30-minute infusion) versus gemcitabine (fixed-dose-rate infusion (FDR) versus gemcitabine + oxaliplatin (GEMOX) in patients with advanced pancreatic cancer (E6201). [abstr] J Clin Oncol. 2006;24(suppl):LBA4004
  21. Louvet C, Libianca R, Hammel P, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: Results of a GERCOR and GISCAD phase III trial. J Clin Oncol. 2005;23:3509–3516
  22. Cunningham D, Chau I, Stocken D, et al. Phase III randomised comparison of gemcitabine versus gemcitabine plus capecitabine (GEM-CAP) in patients with advanced pancreatic cancer. [abstr PS11] Eur J Cancer. 2005;3(suppl 4):4
  23. Kindler HL, Friberg G, Singh D, et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2005;23:8033–8040
  24. Xiong HQ, Rosenberg A, LoBuglio A, et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: A multicenter phase II trial. J Clin Oncol. 2004;22:2610–2616
  25. Conroy T, Paillot B, François E, et al. Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer – A Group Tumeurs Digestives of the Fédération Nationale des Centres de Lutte Contre le Cancer Study. J Clin Oncol. 2005;23:1228–1236
  26. Herrmann R, Bodoky G, Ruhstaller T, et al. Gemcitabine plus capecitabine versus gemcitabine alone in locally advanced or metastatic pancreatic cancer (A randomized study of the Swiss Group for Clinical Cancer Research (SAKK) and the Central European Cooperative Oncology Group (CECOG)). [abstr] J Clin. 2005;23(suppl):4010
  27. Ozawa F, Friess H, Tempia-Caliera A, et al. Growth factors and their receptors in pancreatic cancer. Teratog Carcinog Mutagen. 2001;21:27–44
  28. Hoffmann-La Roche Media News: US phase III study of Avastin in advanced pancreatic cancer does not meet primary endpoint. Available at: http://www.roche.com/med-cor-2006-06-27 (accessed October 31, 2006)
  29. Ducreux M, Mitry E, Ould-Kaci M, et al. Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients. Ann Oncol. 2004;15:467–473
  30. Mitry E, Ducreux M, Ould-Kaci M, et al. Oxaliplatin combined with 5-FU in second line treatment of advanced pancreatic adenocarcinoma (Results of a phase II trial). Gastroenterol Clin Biol. 2006;30:357–363

PII: S0093-7754(07)00023-1

doi: 10.1053/j.seminoncol.2007.01.006

Seminars in Oncology
Volume 34 , Pages S25-S30 , April 2007

Article Tools

* Image Usage & Resolution